Anthony Brown
Research Assistant
Brief Biography:
I’ve been working with Professor Barnes since 2007 and have mainly been working on the Phase 1 clinical candidate HCV vaccine studies that have been carried out in Oxford, looking at their immunogenicity in healthy volunteers and HCV patients.
I have also been involved in the NGS work of various pathogenic viruses, particularly HCV, that has been set up in collaboration with the Welcome Trust Centre for Human Genomics.
In addition to these main roles I have been looking at the immune response to HEV in HEV exposed individuals from Cornwall and Oxford in a collaboration with Dr Harry Dalton.
Research interests:
HCV sequencing and vaccination, all aspects of HEV infection and viral sequencing
Current projects:
PEACHI vaccine study, STOP-HCV viral sequencing and host immune response to HEV infection
Recent publications
The development of a pan-genotypic T cell vaccine against hepatitis C virus using heterologous prime-boost strategies.
Journal article
Strain R. et al, (2025), Hepatology
Phase Ib/IIa randomized study of heterologous ChAdOx1-HBV/MVA-HBV therapeutic vaccination (VTP-300) as monotherapy and combined with low-dose nivolumab in virally-suppressed patients with CHB.
Journal article
Tak WY. et al, (2024), J Hepatol, 81, 949 - 959
Obesity differs from diabetes mellitus in antibody and T-cell responses post-COVID-19 recovery.
Journal article
Ali M. et al, (2024), Clin Exp Immunol, 218, 78 - 92
Hybrid adaptive immunity to SARS-CoV-2 protects against breakthrough infection after COVID-19 vaccination in ALSPAC participants
Preprint
Baum HE. et al, (2024)
Immunogenicity of COVID-19 vaccines in patients with follicular lymphoma receiving frontline chemoimmunotherapy.
Journal article
Lim YJ. et al, (2024), Br J Haematol, 205, 440 - 451